References
- Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
- Faderl S, Talpaz M, Estrov Z, et al. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999;131:207-19
- Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012;26:2197-203
- Fava C, Rege-Cambrin G, Saglio G. Chronic myeloid leukemia: state of the art in 2012. Curr Oncol Rep 2012;14:379-86
- Breccia M, Alimena G. How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages. Cancer Lett 2012;322:127-32
- LeukemiaNet E. Recommendations from the European LeukemiaNet for the Management of Chronic Myeloid Leukemia (CML). 2010. Available at: http://www.leukemia-net.org/content/leukemias/cml/recommendations/e8078/infoboxContent8096/PocketCard_2010_final.pdf [Last accessed 1 December 2013]
- Network NCC. Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia (v 4.2013). 2013. Available at: http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf [Last accessed 1 December 2013]
- Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011;117:3733-6
- Marin D, Bazeos A, Mahon F-X, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381-8
- Noens L, van Lierde M-A, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401-11
- Weingart SN, Brown E, Bach PB, et al. NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw 2008;6(Suppl 3):S1-14
- Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009;59:56-66
- Wu EQ, Johnson S, Beaulieu N, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010;26:61-9
- St Charles M, Bollu VK, Hornyak E, et al. Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia. Blood 2009;114:2209 . Available at: https://ash.confex.com/ash/2009/webprogram/Paper23447.html [Last accessed 18 March 2014]
- Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007;25:481-96
- Tsang J, Rudychev I, Pescatore SL. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). J Clin Oncol 2006 ASCO Annu Meet Proc (Post-Meeting Ed. 2006;24, No 18S:6119). Available at: http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/6119 [Last accessed 1 December 2013]
- Elixhauser A, Steiner C, Kruzikas D. HCUP Methods Series Report # 2004-1. ONLINE February 6, 2004. U.S. Agency for Healthcare Research and Quality. Comorbidity Softw Doc 2004:12–15. Available at: http://www.hcup-us.ahrq.gov/reports/ComorbiditySoftwareDocumentationFinal.pdf [Last accessed 1 December 2013]
- Schneeweiss S, Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol 2000;29:891-8
- Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12
- Guérin A, Chen L, Dea K, et al. Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia. J Med Econ 2014;17:89-98
- Wu EQ, Guerin A, Yu AP, et al. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin 2010;26:2861-9
- Goldberg SL, Chen L, Guerin A, et al. Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib. Curr Med Res Opin 2013;29:1075-82
- Jabbour E, Kantarjian H, Ghanem H, et al. The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. Clin Lymphoma Myeloma Leuk 2013;13:302-6
- Partridge AH, Avorn J, Wang PS, et al. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002;94:652-61
- Osterberg L, Terrence B. Adherence to medication. N Engl J Med 2005;353:487-97